Skip to content

Author

Julio Luna

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Urinary Biomarker Analysis of the SANCTUARY Trial: Insights into IgA Nephropathy Pathophysiology and Ravulizumab Mechanism of Action.

BACKGROUND Complement activation in IgA nephropathy (IgAN) drives inflammation, nephron loss, and progressive kidney damage. We evaluated urinary biomarkers among participants with IgAN treated with ravulizumab (terminal complement C5 inhibitor) versus placebo in the Phase 2 SANCTUARY trial and healthy donors. METHOD...

T. J. Cammett, E. Millman, Julio Luna et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.